OTCMKTS:MLLCF Molecular Partners (MLLCF) Stock Price, News & Analysis $4.01 0.00 (0.00%) As of 10/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Molecular Partners Stock (OTCMKTS:MLLCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Molecular Partners alerts:Sign Up Key Stats Today's Range$4.01▼$4.0150-Day Range$3.80▼$4.0152-Week Range$2.25▼$4.85VolumeN/AAverage Volume1,060 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland. The company discovers and develops protein therapeutics based on its proprietary DARPin platform, which uses engineered ankyrin repeat proteins to create targeted and potentially multi-specific medicines. Molecular Partners’ research focuses primarily on oncology, immuno-oncology and other serious diseases in which precisely targeted protein therapies may offer therapeutic advantages. Its development programs are designed to engage multiple biological targets or immune pathways and may include both wholly owned and partnered drug candidates. The company has also developed ensovibep, a DARPin-based antiviral candidate that was evaluated for COVID-19. Founded in 2004, Molecular Partners has established collaborations with pharmaceutical and biotechnology companies to advance DARPin-based therapeutics. The company is listed on the SIX Swiss Exchange and its shares also trade over the counter in the United States. Molecular Partners is led by Chief Executive Officer Patrick Amstutz, who has been associated with the company’s development since its early years.AI Generated. May Contain Errors. Read More Receive MLLCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLLCF Stock News HeadlinesMolecular Partners AG MLLCFOctober 1, 2026 | morningstar.comMMolecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with CholangiocarcinomaJuly 16, 2026 | markets.businessinsider.comElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 16 at 1:00 AM | Brownstone Research (Ad)First patient dosed in Molecular and Orano Med’s MP0712 trialJuly 6, 2026 | msn.comMolecular Partners AG to Present MP0712 Phase 1/2a Study Findings at 2026 ASCO and SNMMI Annual MeetingsMay 30, 2026 | quiverquant.comQMolecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation SummitMay 26, 2026 | markets.businessinsider.comMolecular Partners AG to Present Lead Radio-DARPin Candidate MP0712 at Upcoming Scientific ConferencesMay 4, 2026 | quiverquant.comQMolecular Partners AG Announces Positive Phase 1 Results for MP0317 Demonstrating Tumor-Localized CD40 Activation and Initiation of Phase 2 Trial in CholangiocarcinomaMay 1, 2026 | quiverquant.comQSee More Headlines MLLCF Stock Analysis - Frequently Asked Questions How have MLLCF shares performed this year? Molecular Partners' stock was trading at $3.50 at the beginning of 2026. Since then, MLLCF shares have increased by 14.6% and is now trading at $4.01. How do I buy shares of Molecular Partners? Shares of MLLCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/16/2026Next Earnings (Estimated)10/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:MLLCF CIKN/A Webwww.molecularpartners.com Phone(144) 755-7700FaxN/AEmployees167Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:MLLCF) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
